{"entity":{"id":"nct07553390","kind":"trial","name":"Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07553390 as not yet recruiting, last updated 2026-08-19. Enrolment is 60 planned participants, an estimate. Interventions: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07553390","url":"https://clinicaltrials.gov/study/NCT07553390"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07553390","phase":"1","setting":"Phase 1b Study Of Allogeneic CAR TROP2/IL15 Transduced TGFBR2 KO CB NK-Cells (TRICK-NK) In Combination With Trastuzumab Deruxtecan (T-Dxd) In Treatment-Refractory Breast Cancers","sponsor":"M.D. Anderson Cancer Center","started":"2026-10-01","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07553390/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}